Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.

about

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

P2860

Q54983769-60B9D78B-EE9A-4E87-88E4-FDAB6F4A8BFE

P2860

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.

Item

http://www.wikidata.org/entity/Q38378641

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Ceritinib in patients with adv ...... ranged NSCLC: Japanese subset.

@en

type

Item

label

Ceritinib in patients with adv ...... ranged NSCLC: Japanese subset.

@en

prefLabel

Ceritinib in patients with adv ...... ranged NSCLC: Japanese subset.

@en

P1476

Ceritinib in patients with adv ...... ranged NSCLC: Japanese subset.

@en

P2093

Ben Hatano

http://www.w3.org/2001/XMLSchema#string

Haruyasu Murakami

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nokihara

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Nakagawa

http://www.w3.org/2001/XMLSchema#string

Kota Tokushige

http://www.w3.org/2001/XMLSchema#string

Makoto Nishio

http://www.w3.org/2001/XMLSchema#string

Miyako Satouchi

http://www.w3.org/2001/XMLSchema#string

Shingo Matsumoto

http://www.w3.org/2001/XMLSchema#string

Takashi Seto

http://www.w3.org/2001/XMLSchema#string

Toyoaki Hida

http://www.w3.org/2001/XMLSchema#string

P2860

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYX045

http://www.w3.org/2001/XMLSchema#string

P50

Katsuyuki Kiura

P577

2017-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28369553

http://www.w3.org/2001/XMLSchema#string

P921

ceritinib

crizotinib

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.

about

P2860

P2860

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P921